Cargando…

Ketamine Does Not Exert Protective Properties on Dopaminergic Neurons in the Lactacystin Mouse Model of Parkinson’s Disease

Parkinson’s disease (PD) is an age-related neurodegenerative condition characterized by a progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc). A loss of proteasome function participates to the pathogenesis of PD, leading to the development of rodent models in which...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deneyer, Lauren, Massie, Ann, Bentea, Eduard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156534/ https://www.ncbi.nlm.nih.gov/pubmed/30283309 http://dx.doi.org/10.3389/fnbeh.2018.00219

Ejemplares similares

Caloric Restriction Protects against Lactacystin-Induced Degeneration of Dopamine Neurons Independent of the Ghrelin Receptor
por: Coppens, Jessica, et al.
Publicado: (2017)

Aged xCT-Deficient Mice Are Less Susceptible for Lactacystin-, but Not 1-Methyl-4-Phenyl-1,2,3,6- Tetrahydropyridine-, Induced Degeneration of the Nigrostriatal Pathway
por: Bentea, Eduard, et al.
Publicado: (2021)

Associated degeneration of ventral tegmental area dopaminergic neurons in the rat nigrostriatal lactacystin model of parkinsonism and their neuroprotection by valproate
por: Harrison, Ian F., et al.
Publicado: (2016)

The Proteasome Inhibition Model of Parkinson’s Disease
por: Bentea, Eduard, et al.
Publicado: (2017)

Selenoprotein T Exerts an Essential Oxidoreductase Activity That Protects Dopaminergic Neurons in Mouse Models of Parkinson's Disease
por: Boukhzar, Loubna, et al.
Publicado: (2016)

Lactacystin-induced kidney fibrosis: Protection by melatonin and captopril
por: Repova, Kristina, et al.
Publicado: (2022)

Anchanling reduces pathology in a lactacystin- induced Parkinson's disease model☆
por: Li, Yinghong, et al.
Publicado: (2012)

Chronic Sulfasalazine Treatment in Mice Induces System x(c) (−) - Independent Adverse Effects
por: Verbruggen, Lise, et al.
Publicado: (2021)

The histone deacetylase inhibitor nicotinamide exacerbates neurodegeneration in the lactacystin rat model of Parkinson's disease
por: Harrison, Ian F., et al.
Publicado: (2018)

Formal synthesis of (+)-lactacystin from l-serine
por: Bulman Page, Philip C., et al.
Publicado: (2019)

CLR01 protects dopaminergic neurons in vitro and in mouse models of Parkinson’s disease
por: Bengoa-Vergniory, Nora, et al.
Publicado: (2020)

Oxidative Stress in Genetic Mouse Models of Parkinson's Disease
por: Varçin, Mustafa, et al.
Publicado: (2012)

12.3 SYSTEM XC- AS A NOVEL MODULATOR OF CORTICOSTRIATAL NEUROTRANSMISSION
por: Bentea, Eduard, et al.
Publicado: (2018)

Progranulin Gene Delivery Protects Dopaminergic Neurons in a Mouse Model of Parkinson’s Disease
por: Van Kampen, Jackalina M., et al.
Publicado: (2014)

Lactacystin-Induced Model of Hypertension in Rats: Effects of Melatonin and Captopril
por: Simko, Fedor, et al.
Publicado: (2017)

BMP5/7 protect dopaminergic neurons in an α-synuclein mouse model of Parkinson’s disease
por: Vitic, Zagorka, et al.
Publicado: (2020)

Knockout or inhibition of USP30 protects dopaminergic neurons in a Parkinson’s disease mouse model
por: Fang, Tracy-Shi Zhang, et al.
Publicado: (2023)

Moxibustion Protects Dopaminergic Neurons in Parkinson's Disease through Antiferroptosis
por: Huang, Zifeng, et al.
Publicado: (2021)

Parkinson's disease and dopaminergic neurons
Publicado: (2012)

Sodium Phenylbutyrate Controls Neuroinflammatory and Antioxidant Activities and Protects Dopaminergic Neurons in Mouse Models of Parkinson’s Disease
por: Roy, Avik, et al.
Publicado: (2012)

Inhibition of repulsive guidance molecule-a protects dopaminergic neurons in a mouse model of Parkinson’s disease
por: Oda, Wakana, et al.
Publicado: (2021)

Lack of Neuroprotective Effect of Celastrol Under Conditions of Proteasome Inhibition by Lactacystin in In Vitro and In Vivo Studies: Implications for Parkinson’s Disease
por: Konieczny, Jolanta, et al.
Publicado: (2014)

Parkinson’s Disease, the Dopaminergic Neuron and Gammahydroxybutyrate
por: Mamelak, Mortimer
Publicado: (2018)

Repetitive transcranial magnetic stimulation for treatment of lactacystin-induced Parkinsonian rat model
por: Ba, Maowen, et al.
Publicado: (2017)

Irisin protects the substantia nigra dopaminergic neurons in the rat model of Parkinson’s disease
por: Zarbakhsh, Sam, et al.
Publicado: (2019)

Src Inhibition Attenuates Neuroinflammation and Protects Dopaminergic Neurons in Parkinson’s Disease Models
por: Yang, Hanyu, et al.
Publicado: (2020)

Taurine protects dopaminergic neurons in a mouse Parkinson’s disease model through inhibition of microglial M1 polarization
por: Che, Yuning, et al.
Publicado: (2018)

Focused Ultrasound Promotes the Delivery of Gastrodin and Enhances the Protective Effect on Dopaminergic Neurons in a Mouse Model of Parkinson’s Disease
por: Wang, Yuhong, et al.
Publicado: (2022)

Vulnerability of Mesostriatal Dopaminergic Neurons in Parkinson's Disease
por: González-Hernández, Tomás, et al.
Publicado: (2010)

Lactacystin: first-in-class proteasome inhibitor still excelling and an exemplar for future antibiotic research
por: Ōmura, Satoshi, et al.
Publicado: (2019)

Gastrodin Protects Apoptotic Dopaminergic Neurons in a Toxin-Induced Parkinson's Disease Model
por: Kumar, Hemant, et al.
Publicado: (2013)

Smilagenin Protects Dopaminergic Neurons in Chronic MPTP/Probenecid—Lesioned Parkinson’s Disease Models
por: He, Xuan, et al.
Publicado: (2019)

Presence of proNGF-Sortilin Signaling Complex in Nigral Dopamine Neurons and Its Variation in Relation to Aging, Lactacystin and 6-OHDA Insults
por: Xia, Yi, et al.
Publicado: (2013)

Necrostatin-1 protection of dopaminergic neurons
por: Wu, Jing-ru, et al.
Publicado: (2015)

Ketamine enhances structural plasticity in human dopaminergic neurons: possible relevance for treatment-resistant depression
por: Collo, Ginetta, et al.
Publicado: (2018)

Structural Plasticity Induced by Ketamine in Human Dopaminergic Neurons as Mechanism Relevant for Treatment-Resistant Depression
por: Collo, Ginetta, et al.
Publicado: (2019)

Roles of FGF20 in dopaminergic neurons and Parkinson's disease
por: Itoh, Nobuyuki, et al.
Publicado: (2013)

microRNA‐221 rescues the loss of dopaminergic neurons in a mouse model of Parkinson's disease
por: Yao, Yufang, et al.
Publicado: (2023)

The Protective Effect of Repeated 1MeTIQ Administration on the Lactacystin-Induced Impairment of Dopamine Release and Decline in TH Level in the Rat Brain
por: Wąsik, Agnieszka, et al.
Publicado: (2018)

No synergism between bis(propyl)-cognitin and rasagiline on protecting dopaminergic neurons in Parkinson's disease mice
por: Zheng, Cheng-you, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_9buc34gdt4ek1tvvoosv0d32mm